Identification and characterization of novel fusion genes in prostate cancer by targeted RNA capture and next-generation sequencing  

作　　者：Jie Yang Yun Chen Jingxiao Lu Xingxing Wang Lu Wang Jialong Liang Zhong Sheng Sun 

机构地区：[1]Institute of Genomic Medicine,Wenzhou Medical University,Wenzhou 325000,China [2]Biobank of the Second People's Hospital,The First Affiliated Hospital of Shenzhen University,Shenzhen 100730,China [3]Key Laboratory of Developmental Genes and Human Diseases,Institute of Life Sciences,Southeast University,Nanjing 210096, China [4]Beijing Institutes of Life Science,Chinese Academy of Sciences,Beijing 100000,China

出　　处：《Acta Biochimica et Biophysica Sinica》2018年第11期1166-1172,共7页生物化学与生物物理学报（英文版）

摘　　要：Gene fusions play critical roles in the development and progression of prostate cancer,and have been used as molecular biomarkers for diagnosis of the malignant disease.To further explore the novel fusions in prostate cancer,we performed targeted RNA capture and next-generation sequencing in a cohort of 52 prostate cancer patients,identified and validated 14 fusion events (7 types of fusion genes)in 12 cases,including three novel fusion genes.We characterized a chromosome rearrangement-induced trigenic KLK2-DGKB-ETV1 fusion,which may function as a noncoding RNA to upregulate the expression of the wild-type ETV1 protein in the tumor tissue. Additionally,we detected two novel fusion forms of HNRNPA2B1-ETV1 and SLC45A2-AMACR fusions,respectively.Interestingly,fusion events participated by kinase genes,which frequently occurred in other human cancers,were not present in these prostate cancer cases,suggesting discrepant gene fusion patterns in different cancers.These findings expand the genetic spectrum of prostate cancer and provide insight into diagnosis of this prevalent disease.

关 键 词：gene fusion PROSTATE cancer ETVI TARGETED RNA CAPTURE next-generation sequencing 

分 类 号：Q[生物学]